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Whilst there appears to be no ergogenic effect from inhaled 
salbutamol no study has investigated the impact of the acute 
inhalation of 1600 µg, the World Anti-Doping Agency (WADA) 
daily upper limit, on endurance running performance. To inves-
tigate the ergogenic effect of an acute inhalation of short acting 
β2-agonists at doses up to 1600 µg on 5 km time trial perform-
ance and resultant urine concentration. Seven male non-
asthmatic runners (mean ± SD; age 22.4 ± 4.3 years; height 1.80 
± 0.07 m; body mass 76.6 ± 8.6 kg) provided written informed 
consent. Participants completed six 5 km time-trials on separate 
days (three at 18 oC and three at 30 oC). Fifteen minutes prior to 
the initiation of each 5 km time-trial participants inhaled:  pla-
cebo (PLA), 800 µg salbutamol (SAL800) or 1600 µg salbuta-
mol (SAL1600). During each 5 km time-trial HR, VO2, VCO2, 
VE, RPE and blood lactate were measured. Urine samples (90 
ml) were collected between 30-180 minutes post 5 km time-trial 
and analysed for salbutamol concentration. There was no sig-
nificant difference in total 5 km time between treatments (PLA 
1714.7 ± 186.2 s; SAL800 1683.3 ± 179.7 s; SAL1600 1683.6 ± 
190.7 s). Post 5 km time-trial salbutamol urine concentration 
between SAL800 (122.96 ± 69.22 ug·ml-1) and SAL1600 
(574.06 ± 448.17 ug·ml-1) were not significantly different. There 
was no improvement in 5 km time-trial performance following 
the inhalation of up to 1600 µg of salbutamol in non-asthmatic 
athletes. This would suggest that the current WADA guidelines, 
which allow athletes to inhale up to 1600 µg per day, is suffi-
cient to avoid pharmaceutical induced performance enhance-
ment.  
 







Between 2002 and 2010, the International Olympic 
Committee (IOC) required athletes to present evidence of 
current asthma or exercise induced bronchoconstriction 
(EIB) in order to use inhaled β2-Agonists. Initially this 
was conducted independently by the IOC for the Olympic 
Games and followed by a global requirement, via the 
World Anti-Doping Agency (WADA), incorporating it 
into the Therapeutic Use Exemption (TUE) certificate 
system. These regulations, guided by the IOC Medical 
Commission (IOC-MC), were based on health not doping 
(performance enhancing) concerns for athletes in light of 
a marked increase in the notification for the use of inhaled 
short acting β2-agonist from 3.7% at the Atlanta Olympic 
Games, 1996, to 5.7% at the Sydney Olympic Games, 
2000 (Fitch et al., 2008). Examining the prevalence of 
asthma and EIB in Great British Olympic athletes across 
two summer Olympic cycles (2000 and 2004) we pro-
vided support for the health justification of adding inhaled 
short acting β2-agonist to the prohibited list (Dickinson et 
al., 2005). Our data demonstrated that the requirement for 
a TUE for the use of inhaled short acting β2-agonist had 
no impact on the proportion of Great British Olympic 
team athletes presenting with asthma, EIB or AHR be-
tween the 2000 Sydney Olympic Games and the 2004 
Athens Olympic Games (~21% at both) however; we 
identified a number of athletes with false positive diagno-
ses and athletes who had not been previously identified. 
Accordingly, we concluded, as have others, that the re-
quirement of demonstrable evidence through the TUE 
process improves the quality of care for athletes (Couto et 
al., 2013). Furthermore, data from our lab (Dickinson et 
al., 2006a; 2006b) and others (Anderson et al., 2003; 
Parsons et al., 2007; Rundell et al., 2004,) has demon-
strated the improved diagnostic sensitivity and specificity 
of incorporating indirect airway challenges into the proc-
ess of diagnosing an athlete with asthma, EIB or AHR. 
The weight of evidence supports the improved 
health care of athletes following the introduction of the 
TUE process for inhaled short acting β2-agonist (Fitch et 
al. 2008; Couto et al. 2013). In recent years it has been 
argued that the requirement of a TUE is not warranted due 
to the limited evidence to suggest doses of inhaled β2-
agonist (200 – 800 µg) have a significant ergogenic ef-
fect. A meta-analysis, incorporating the small numbers of 
studies that do exist, reported no performance improve-
ment in endurance performance from up to 800 µg of 
inhaled short acting β2-agonist (Pluim et al., 2011). How-
ever the requirement of needing a TUE to use inhaled β2-
agonist therapist may also lead to athletes requiring inhal-
ers for asthma/EIB not taking them in order to not risk a 
doping violation.   
Whilst there appears to be no ergogenic effect from 
inhaled salbutamol at low doses, no study has investigated 
the impact of inhaling the World Anti-Doping Agency 
(WADA) daily upper limit of 1600 µg (~16 inhalations of 
a standard salbutamol inhaler; WADA, 2013) on endur-
ance running performance. Furthermore, only a limited 
number of studies have examined the salbutamol elimina-
tion in urine of inhaled doses as high as 1600 µg and have 
reported urine concentrations close to the WADA upper 
limit of 1000 ng.ml-1. Of note, these studies have failed to 
compare high dose administration of short acting β2-
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agonist with an intermediate dose (800µg) and placebo.  
They have also focussed on multiple dosing regimens 
such as 4 x 400 µg of salbutamol as opposed to a single 
high dose (Elers et al., 2011). Whilst athletes are usually 
prescribed 200-400 µg of inhaled salbutamol our experi-
ence suggests that athletes are often prescribed inhaled 
salbutamol pro re nata (i.e. on an as needed basis) that 
could be interpreted as a clearance to inhale unlimited 
amounts of salbutamol to combat respiratory symptoms. 
Indeed, recently a Rugby League player escaped a doping 
violation after he inhaled over 1600 µg over the course of 
a match and then tested positive in the post-match anti-
doping test. The players defence was based on the pre-
scription of inhaled salbutamol was on an ‘as needed 
basis’ with no guidance on an upper limit to its use. Ac-
cordingly, in practice 16 inhalations in a short period of 
time prior to and during competition may occur in poorly 
controlled, less informed or unscrupulous athletes. Yet 
these athletes are working within the recommended limit 
stated on the 2014 Prohibited List. Furthermore, the im-
pact of exercising in a hot environment, resulting in sig-
nificant dehydration, may have a profound effect on urine 
concentrations.  
To date, no studies have examined the impact of a 
hot environment on combined Salbutamol administration 
(up to 1600 µg) and endurance running performance, or 
on the resultant salbutamol elimination in urine. Accord-
ingly, the purpose of this study was to contribute to the 
understanding of the potential ergogenic effect of inhaled 
short acting β2-agonists at doses up to and including the 
maximal dose as stipulated on the WADA 2014 Prohib-
ited List (WADA, 2014) on endurance exercise. In addi-
tion, we examined the salbutamol elimination in urine 
following exercise in temperate (18°C) and hot (30°C) 
environments. 
 
Methods   
 
Prior to the commencing the study ethical approval was 
obtained from Liverpool John Moores University Local 
Ethics Committee (ethics no: 09E18GW). Seven male 
runners (mean ± SD; age 22.4 ± 4.3 years; height 1.80 ± 
0.07 m; body mass 76.6 ± 8.6 kg) volunteered and pro-
vided written and verbal informed consent. All partici-
pants were free from asthma, EIB and AHR confirmed by 
no previous history of disease and presenting with a nega-
tive Eucapnic Voluntary Hyperpnoea (EVH) challenge 
(Anderson et al., 2001). All participants were free from 
chest infection for at least 4 weeks prior to assessment; 
they were not taking any medication and there were no 
other health or medical contradictions to them taking part 
in the study as confirm by information provided on a 
physical activity readiness questionnaire. All participants 
were actively engaged in endurance running training (>45 
minutes continuous running) at least 3 time per week. 
Participants were required to complete six 5 km time-
trials; 3 in a temperate environment (18°C, 40% Relative 
Humidity (RH)) and 3 in a hot (30°C, 40% RH) environ-
ment. Fifteen minutes prior the initiation of each 5 km 
time-trial participants inhaled one of the following treat-
ments,  via  a  pocket  chamber,  in  a randomised, double- 
blind design:  
 
Temperate (18°C, 40% RH): 
Treatment 1: 16 inhalations of placebo (PLA) 
Treatment 2: 8 inhalations of 100 µg salbutamol, 8 
inhalation of placebo (SAL800) 
Treatment 3: 16 inhalations of 100 µg salbutamol 
(SAL1600) 
 
Hot (30°C, 40% RH) 
Treatment 4: 16 inhalations of placebo (PLA) 
Treatment 5: 8 inhalations of 100 µg salbutamol, 8 
inhalation of placebo (SAL800) 
Treatment 6: 16 inhalations of 100 µg salbutamol 
(SAL1600) 
 
5 km time trial 
Participants were familiarised to running on a non-
motorised treadmill (Woodway Curve, Woodway, USA) 
prior to initiating the 5 km time-trials. Familiarisation 
runs took place over a distance of 5 km on at least two 
occasions. Participants progressed to the recorded 5 km 
time-trials once they felt comfortable pacing themselves 
on the non-motorised treadmill over the 5 km distance. 
Each time-trial was conducted under controlled la-
boratory conditions: Temperate (18°C, relative humidity 
40%), and Hot (30oC, relative humidity 40%). Prior to 
starting the time-trial participants were fitted with a heart 
rate monitor (Polar RS400; Polar Electro Oy, Kempele, 
Finland) and connected to a breath-by-breath gas analyser 
via a face mask (Oxycon Pro, Jagear, Wuerzberg, Ger-
many). Over the course of the 5 km time-trial the follow-
ing were measured: time, average heart rate (HR), oxygen 
consumption (VO2), carbon dioxide production (VCO2), 
minute ventilation (VE), respiratory exchange ratio (RER) 
and rating of perceived exertion (RPE). Two minutes 
following the completion of the 5 km time-trial capillary 
blood lactate was measured (Lactate Pro, Arkray KDK, 
Japan).  
During the 5 km time-trial participants were only 
given feedback on the distance they had covered. They 
were blinded to all other feedback such as time and HR. 
Participants were encouraged to complete the time-trial as 
fast as possible with prizes offered to the five fastest 
times. During the time-trial consistent positive encour-
agement was given to each participant.  
 
Maximal flow-volume loops 
Three maximal flow-volume loops were measured (Mi-
croLab Spriometer ML3500, Cardinal Health, Chatham 
Maritime, UK) at baseline, 10 minutes after inhalation of 
PLA, SAL800 and SAL1600 and then 10 minutes post-5 
km time-trial. On each occasion maximal flow volumes 
were measured according to the European Respiratory 
Society criteria (Miller et al., 2005). At each time point 
Forced Expiratory Volume in One Second (FEV1), Forced 
Vital Capacity (FVC), Peak Expiratory Flow (PEF) and 
Forced Expiratory Flow between 25 % and 75 % of FVC 
(FEF25-75) were measured. 
 
Urine collection 






asked to provide a urine sample in order to void them-
selves of urine, after which placebo or Salbutamol was 
administered as described above. Subjects were instructed 
to collect the first sample of urine passed following com-
pletion of the laboratory-based tests in line with in-
competition anti-doping procedures as outlined in the 
World Anti-Doping Code International Standard for Test-
ing 2012. Urine samples were provided by participants 
between 30 and 180 minutes following the completion of 
the 5 km time trails.  Consumption of water during this 
period was encouraged ad libitum to ensure diuresis. 
From the sample provided by each subject a 20 ml aliquot 
of urine was stored at -80oC until analysis. 
 
Urinalysis 
All urinalysis was performed at HFL Sport Science 
(Fordham, UK) an independent drug surveillance labora-
tory and former WADA-accredited laboratory. Sample 
preparation involved the addition of 200 ng of Salbuta-
mol-D3 (NMI) as an internal standard to 1 ml of urine. 
Following the addition of 2 ml of 0.1M phosphate buffer 
pH 6.8 and 100 µl of E. Coli enzyme (β-glucuronidase) 
solution the mixture was incubated overnight at 37oC. 
Strata XC 60 mg solid phase extraction cartridges (Phe-
nomenex, Macclesfield, UK) were conditioned with 3 ml 
of methanol followed by 3 ml of reagent grade water. 
Following centrifugation at 3500 rpm for 5 min the sam-
ples were applied to the cartridges. The cartridges were 
then washed with 3 ml of 0.1M acetate buffer pH 9.0 
followed by 3 ml of reagent grade water, 3 ml of 0.1M 
HCl, 3 ml of methanol and 3 ml of diethyl ether. The 
cartridges were then dried for 5 min under vacuum and 
samples were eluted into glass vials with two, 1 ml of 
basic drug elution solvent (160 ml ethyl acetate, 34 ml 
propan-2-ol and 6 ml 34% ammonia solution). Samples 
were then evaporated to dryness at ambient temperature 
using a centrifugal vacuum concentrator (Genevac Ltd, 
Ipswich, UK) and reconstituted in 10 µl of isopropanol 
followed by 200 µl of basic reconstitution solution (495 
ml of 0.1 acetic acid mixed with 5 ml Benzyldimethyl-
phenyl  Ammonium).  Samples  were centrifuged at 3000  
rpm for 10 min prior to LCMS submission. Samples were 
injected onto a Thermo Scientific Accela HPLC system 
coupled to a Thermo Scientific LTQ Orbitrap Discovery 
Mass Spectrometer (Thermo Fisher Scientific, Waltham, 
USA). Chromatographic separation was performed on a 
Waters Atlantis T3 column (2.1 x 100 mm, particle size 3 
um; Waters Ltd, Elstree, UK) at 35oC. The mobile phase 
was a gradient system of 0.1% acetic acid aqueous solu-
tion containing uracil (300 ng·ml-1) and 0.1% acetic acid 
in acetonitrile containing uracil (300 ng.ml-1) set at a flow 
rate of 0.4 ml·min-1.  
The urine salbutamol concentrations reported cor-
respond to the sum of the free and glucuronide conju-
gates. The samples were analysed over the calibration 
range of 10 to 2000 ng·ml-1. The lower limit of quantifica-
tion was accepted as the lowest standard on the calibra-
tion curve (10 ng·ml-1) 
 
Statistical analysis 
Total time to complete the 5 km time-trial under each of 
the conditions was analysed by a repeated measures 
ANOVA. Similar analyses were undertaken for HR, VO2, 
VCO2, VE, RER, RPE, blood lactate, FEV1, FVC, PEF 
and FEF25-75. A p-value of ≤0.05 was deemed significant 




Throughout all trials participants reported no side effects 
from inhalation of up to 1600 µg inhaled salbutamol.  
 
Performance trial (hot: 18°C, 40% RH) 
All seven participants completed all three 5 km time-
trials. No significant difference was noted for overall 
completion time between trials (see Figure 1). Further-
more, over each 1 km split no significant difference be-
tween conditions for mean: time; HR; VO2; VCO2; VE; 
and RER were observed (see Figure 2). There was no 
significant difference between conditions in the post 5 km 
time-trial lactate values (see Figure 2). At 2, 3 and 4 km 






Figure 1. Individual and mean ± SE 5 km time-trial performance under each condition in a temperate envi-
ronment (20OC, 40% RH). 









Figure 2. Mean ± SE for time, HR, VO2, VCO2, VE and RPE at each 1 km split of the temperate (18°C)  5 km time-trial (a-f) 
and post-5 km time-trial blood lactate (g).  * = SAL800 and SAL1600 significantly greater than PLA. 
 
SAL1600 when compared to PLA (Figure 2e). There was 
no significant interaction between Maximal Flow Volume 
measures and condition 10 minutes post-inhalation or 
post-5 km time-trial (see Table 1). 
 
Performance trial (hot: 30°C, 40% RH) 
All seven participants completed all three 5 km time-
trials. No significant difference was noted for overall 
completion time between trials (see Figure 3). Further-
more, over each 1 km split no significant time difference 
between conditions was observed (see Figure 4a.). Aver-
age VO2 during the 1st km was significantly greater (p = 
0.046) during PLA (3.941 ± 0.490 l·min-1) when com-
pared with SAL800 (3.591 ± 0.544 l·min-1) and SAL1600 
(3.516 ± 0.416 l·min-1) trials, however overall mean: HR; 
VO2, VCO2 and RPE during the 5 km time-trial were not 
significantly different between trials (see Figure 4). There 
was no significant difference between conditions in the 








Table 1. Maximal flow-volume values at baseline, 10 minutes post-treatment and post-5 km 
time-trial. Data are menas (±SD). 
  Placebo SAL800 SAL1600 
Baseline FEV1 (l) 4.6 (.9) 4.6 (.9) 4.6 (.9) 
 Predicted FEV1 (%)  106.0 (13.5) 106.1 (14.5) 106.0 (14.8) 
 FVC (l) 5.4 (.9) 5.3 (1.0) 5.2 (1.0) 
 Predicted FVC (%) 103.4 (12.4) 102.0 (13.6) 101.3 (13.4) 
 FEV1 % 86.4 (3.4) 87.4 (3.4) 87.6 (3.4) 
Post Salbutamol FEV1 (l) 4.6 (.9) 4.7 (.9) 4.7 (.9) 
 FVC (l) 5.3 (.9) 5.3 (.9) 5.2 (1.0) 
 FEV1 % 87.1 (3.4) 89.1 (4.1) * 89.4 (4.1) * 
Post 5 km time-trial FEV1 (l) 4.6 (.9) 4.7 (1.0) 4.7 (1.0) 
 FVC (1) 5.1 (1.0) 5.1 (1.0) 5.1 (1.0) 
 FEV1 % 89.9 (5.4) 91.0 (4.7) 92.0 (4.7) 
                              *= significantly greater than PLA. 
 
Urine analysis  
Following inhalation of 800 µg of Salbutamol and a 5 km 
time-trial under temperate (18°C) and hot (30°C) ambient 
conditions mean ± SD urine concentrations were 122.96 ± 
69.22 ng·ml-1 and 138.83 ± 98.11 ng·ml-1, respectively 
(see Figure 5). Following inhalation of 1600 µg of Salbu-
tamol and a 5 km time-trial, mean ± SD urine concentra-
tions were 574.06 ± 448.17 ng·ml-1 and 270.32 ±  183.90 
ng·ml-1 under temperate and hot ambient conditions, re-
spectively (see Figure 5). Whilst there were no significant 
differences between drug urine concentrations under 
either condition there was a high degree of inter-
individual variation following the inhalation of 1600 µg 
of Salbutamol (see Figure 5). Only one sample reached 
the WADA upper limit of 1000 ng.ml-1 (1190 ng·ml-1; in 
the temperate environment) however; the sample failed to 




This is the first study to examine the impact of inhaled 
salbutamol at a dose of 1600 µg versus 800 µg and pla-
cebo on time-trial endurance running performance. Fur-
thermore, this study is the first to examine the salbutamol 
elimination in urine following inhalation of salbutamol at 
a doses of 1600 µg and 800 µg and competitive endurance 
performance in temperate (18oC; 40% RH) and hot (30°C; 
40% RH) environments. The results from the current 
study suggests that inhaling up to 1600 µg of salbutamol 
15 minutes prior to a 5 km time-trial does not result in any 
performance improvement or change in physiological 
function. Previous studies that have focused on inhaled 
salbutamol have generally focused on non-specific per-
formance trials such as time to exhaustion or physiologi-
cal markers of performance (Decorte et al., 2008; Sporer 
et al., 2008). A meta-analysis of previous studies has 
demonstrated no improvement following acute inhalation 
of up to 800 µg of salbutamol on running time to exhaus-
tion, VO2max, peak power, 20 km cycling time-trial and 
total work during a 30 s Wingate test (Pluim et al 2011). 
A recent study by Koch et al. (2013) demonstrated no 
performance enhancement in 10 km cycling time trial 
performance following 400 µg inhaled salbutamol in 
athletes with and without a positive EVH challenge. Our 
data complements previous research by focusing on run-
ning time-trial performance and adds to the current body 
of knowledge by reporting on the current upper WADA 
limit of 1600 µg per day of inhaled salbutamol. Further to 
our data, a recent study by Elers et al. (2011) suggested 
that inhaling an acute dose of up to 4000 µg of salbutamol 
resulted in no improvement in cycling time to exhaustion 






Figure 3. Individual and mean ±SE 5 km time-trial performance under each condition in a hot environment (30OC, 40% RH). 









Figure 4. Mean ±SE for time, VO2, HR, VCO2, and RPE at each 1 km split of the 5 km time-trial (a-e) and post-5 km time-
trial blood lactate (f) during 5 km time-trial in the hot environment (30°C).  
 
performance perspective the current WADA upper limit 
of 1600 µg per day, even in single acute doses, appears 
appropriate for endurance events given the absence of 
improvement in performance in non-asthmatic athletes. 
The main action of inhaled salbutamol is to act as a 
bronchodilator to reverse the bronchoconstriction of air-
way smooth muscle. This results in the asthmatic airway 
becoming dilated resulting in reduced airway resistance, 
leading to improvements in VE and exercise performance 
(Haverkamp et al., 2007). It has been suggested that in-
haled salbutamol may result in a performance improve-
ment by causing a significant bronchodilation in the air-
ways of non-asthmatics leading to an improved VE and 
increased oxygen uptake during exercise. In our study we 
observed a non-significant 0.1 litre improvement in FEV1 
10 minutes post-salbutamol inhalation, which did not 
result in an improvement in VE during the 5 km time-






Figure 5. a) Mean ±SD and b) individual urine SAL concentration (ng·ml-1) post 5 km time trial under temperate (20°C) and 







salbutamol when compared to placebo. Previous studies 
have demonstrated non-significant improvements in FEV1 
of 0.2 l following inhalation of 800 µg, which did not 
result in in greater VE or improved endurance perform-
ance (Decorte et al., 2008). Therefore there is no evidence 
available that up to 1600 µg of inhaled salbutamol results 
in significant bronchodilation, improved VE or improved 
endurance performance. 
Further study is required in a larger cohort to en-
sure an avoidance of Type II error.  A power calculation 
would suggest that to detect a change in 1% in sprint 
performance a sample size of 48 participants would be 
required. Furthermore our participants were not elite 
endurance athletes. Elite athletes could not be included in 
this study as they would have been at risk of a doping 
violation. Therefore we cannot claim our results directly 
represent the effects of inhaled salbutamol in elite endur-
ance athletes.   
The current urinary threshold imposed by WADA 
is intended to enable differentiation between the use of 
oral and inhaled Salbutamol and also approved therapeu-
tic use and misuse. Oral use is associated with perform-
ance enhancement since it typically represents doses in 
the region of 10-fold greater than those following inhala-
tion. Nevertheless, there has been limited research to 
examine this association. From an endurance exercise 
perspective only Collomp et al. (2000) has demonstrated 
enhanced performance whereby short-term oral admini-
stration of salbutamol (12 mg/day for 3 weeks) improved 
time to exhaustion during sub-maximal cycling exercise.  
Caruso et al. (1995) and Martineau et al. (1992) have 
demonstrated an increase in muscle strength following 
prolonged oral administration of salbutamol. Indeed pro-
tein synthesis and muscle hypertrophy have been shown 
to be an effect of β2-agonist use in animal models, par-
ticularly long acting β2-agonists such as Clenbuterol. 
However, research is clearly required to examine further 
the claim that oral administration has a positive impact on 
sports performance.    
There exists some ambiguity in terms of the thera-
peutic use of inhaled Salbutamol. Whilst the recom-
mended maximal dosing regimen for  Salbutamol is 100 
µg to 400 µg up to four times daily, it is typically pre-
scribed pro re nata (when required) which may add to the 
confusion. Individuals encouraged to administer Salbuta-
mol pro re nata may dose over and above the maximal 
recommended daily dose of 1600 µg either intentionally 
or inadvertently, however, in both instances, individuals 
intent to dope for performance enhancement purposes 
may be nil. Such circumstances may lead to the current 
threshold being unintentionally breached and thus bring 
about an adverse analytical finding (AAF). Clearly indi-
viduals administering inhaled Salbutamol up to, and 
above the 1600 µg dose indicates uncontrolled asthma. 
Desensitisation or tolerance are experienced by those 
regularly administering inhaled Salbutamol which not 
only increases the risk of unsuccessful treatment in an 
emergency but also increases the likelihood of further 
overdosing in an attempt to control EIB.  
The current study demonstrates the possibility of a 
urinary Salbutamol concentration above the current 
threshold following therapeutic use. However, whilst the 
WADA Prohibited List threshold is 1000 ng.ml-1 
(WADA, 2014), according to the International Standards 
for Laboratories Technical Document (WADA, 2012) 
Salbutamol should only be reported as an AAF when 
detected at a concentration greater than 1200 ng.ml-1, a 
level referred to as the ‘Decision Limit’. On this basis the 
urinalysis of the current study would not warrant any 
sample to be reported as an AAF. This finding was true 
for a hot (30OC, 40% RH) as well as a temperate envi-
ronment (18OC, 40% RH). The range of salbutamol con-
centrations in our study are similar to Sporer et al. (2008) 
who reported urine concentrations of salbutamol up to 
800 ng·mL-1 60 minutes post time trial following inhala-
tion of 800 µg salbutamol. Elers et al. (2012) reported 
urine salbutamol concentrations peaked between 0-4 
hours. They reported peak salbutamol concentration was 
1057 ng·mL-1 following 800 µg inhaled salbutamol. 
Nevertheless, in our study the inter-individual variation 
was high in both temperate and hot environments and 
combined with the low subject numbers caution is advised 
and future studies should aim to examine the impact of 
high dose Salbutamol (1600 µg) administration on urine 
concentration following endurance performance to estab-
lish the likelihood of the Decision Limit being breached. 
In line with current anti-doping practice the current study 
did not normalise drug concentrations for urine specific 
gravity. Elers et al. (2012) demonstrated that when urine 
samples are corrected for specific gravity no urine sam-
ples following inhalation of 800 µg Salbutamol breached 
the WADA Prohibited List threshold of 1000 ng·ml-1). 
Normalising urine samples for specific gravity may be 
considered by WADA consider in the future.      
A limitation to our study is the variability in actual 
dose inhaled. Whilst the use of a chamber aimed to reduce 
this limitation it remains possible that some participants 
with low urine concentration inhaled lower doses of Sal-
butamol. In addition future work should investigate 
whether there is a relationship between body weight and 
the urinary concentration of salbutamol. A lighter athlete 
may be at a greater risk of breaching the threshold when 
administering high doses compared to a heavier athlete. 
Such findings would have implications to the care athletes 




This study has demonstrated that there is no improvement 
in performance following the inhalation of up to 1600 µg 
of Salbutamol in non-asthmatic athletes in temperate or 
hot environments. This would suggest that the current 
WADA guidelines, which allows athletes to inhale up to 
1600 µg is sufficient to avoid pharmaceutical induced 
enhancement in 5 km running performance. However, 
such high doses not only suggest poor management of 
asthma but also increase the risk of an athlete contraven-
ing the current urinary threshold. 
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• Inhaling up to 1600 µg of Salbutamol does not result 
in improved 5 km time trial performance. 
• The position of Salbutamol on the World Anti-
Doping Agency list of prohibited appears justified. 
• Athletes who use up to 1600 µg Salbutamol in one 
day need to review their therapy as it would suggest 
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